Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05268198




Registration number
NCT05268198
Ethics application status
Date submitted
17/02/2022
Date registered
7/03/2022
Date last updated
2/08/2023

Titles & IDs
Public title
SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects
Scientific title
A Phase 1, Randomized, Blinded, Placebo-Controlled, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APR002 Administered by Inhalation in Healthy Volunteers
Secondary ID [1] 0 0
APR002-NEB-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
COVID-19 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - APR002
Treatment: Drugs - Placebo

Experimental: Intervention/Treatment - Single dose, oral inhalation (nebuliser solution)

Placebo Comparator: Placebo - Placebo


Treatment: Drugs: APR002
Active Investigational Product

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability of APR002 in healthy subjects as assessed by incidence of treatment-emergent adverse events according to CTCAE v5.0 criteria
Timepoint [1] 0 0
Screening up to Day 14
Secondary outcome [1] 0 0
Pharmacokinetics of APR002 in healthy subjects as assessed by maximum plasma concentration (Cmax) towards determination of the optimal pharmacokinetic dose
Timepoint [1] 0 0
Day 1 to Day 3
Secondary outcome [2] 0 0
Pharmacokinetics of APR002 in healthy subjects as assessed by time to maximum concentration (Tmax) towards determination of the optimal pharmacokinetic dose
Timepoint [2] 0 0
Day 1 to Day 3
Secondary outcome [3] 0 0
Pharmacokinetics of APR002 in healthy subjects as assessed by plasma exposure (AUC0-t, AUC0-inf) determination of the optimal pharmacokinetic dose
Timepoint [3] 0 0
Day 1 to Day 3
Secondary outcome [4] 0 0
Pharmacokinetics of APR002 in healthy subjects as assessed by terminal elimination half life (t1/2) determination of the optimal pharmacokinetic dose
Timepoint [4] 0 0
Day 1 to Day 3
Secondary outcome [5] 0 0
Pharmacokinetics of APR002 in healthy subjects as assessed by apparent volume of distribution during the terminal elimination phase after inhalation (extravascular) administration for determination of the optimal pharmacokinetic dose
Timepoint [5] 0 0
Day 1 to Day 3

Eligibility
Key inclusion criteria
- Healthy men or women aged 18 to 55 years (inclusive) with suitable veins for
cannulation or repeated venipuncture.

- Women can be of childbearing potential and must have been stable on a highly effective
contraceptive method for at least 3 months prior to Visit 1 (screening) and be willing
to continue on the chosen contraceptive method

- Male subjects should be willing to use a condom (with spermicide) to prevent pregnancy
and drug exposure of a female partner and refrain from donating sperm or fathering a
child from the day of the investigational product administration until 3 months

- Have a body mass index (BMI) between 18 and 32 kg/m2 and weigh at least 45 kg.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- History or presence of clinically significant medical (e.g., chronic obstructive
pulmonary disease, asthma, COVID-19, etc.) or psychiatric condition or disease

- Abnormal vital signs, after minutes rest, defined as any of the following (SBP > 140
mmHg, Diastolic blood pressure (DBP) > 90 mmHg, Heart rate < 40 or > 99 beats per
minute)

- Prolonged QTcF > 450 ms or family history of long QT syndrome

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 0
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/07/2023
Sample size
Target
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Other
Name
Global Health Drug Discovery Institute
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
CMAX Clinical Research Pty Limited
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Avance Clinical Pty Ltd.
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
of single ascending doses of APR002 in healthy subjects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05268198
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Aaron Weitzman
Address 0 0
Global Health Drug Discovery Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries